ChemDiv, Inc.
6605 Nancy Ridge Drive
San Diego
California
92121
United States
Tel: 858-794-4860
Fax: 858-794-4931
Website: http://www.chemdiv.com/
Email: chemdiv@chemdiv.com
About ChemDiv, Inc.
ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. We engage pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes.Notably, our professional assistance is always custom-tailored to your R&D Chemistry, Biology and Clinical needs. We pride ourselves on being one of the industry's most experienced CROs that deal with every aspect of both early and clinical development of oncology-, CNS-, metabolic-, anti-inflammatory and antiviral therapies. Our track record spans successful and timely delivery of discovery libraries, target-biased compound sets reflective of modern trends in Chemical Biology, pathway analysis, in vitro/ex vivo and in vivo assay development and implementation, a multitude of modern drug discovery and evaluation platforms all aimed at accelerated R&D. The integrated Discovery outSource solutions cover all disciplines needed to bring a project from target ID to Phase II clinical candidate.
Representative examples (for a complete list of services, please visit us at www.chemdiv.com) include protein engineering, production, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK and multiple in vivo efficacy/tox models. Proteomics and biomarker ID capabilities will be added to our portfolio in 2013. Our collaborators range from Pharma/Biotech to academia, foundations and screening centers: every request or project gets equal attention of our expert team.
54 articles about ChemDiv, Inc.
-
ChemDiv Forges Strategic Partnership with The University of Texas Medical Branch (UTMB) to Expand Its High-throughput Screening Research Capabilities
12/28/2023
ChemDiv announces a strategic collaboration with the University of Texas Medical Branch to facilitate the expansion of its inventory and advance the institution's High-throughput Screening research programs.
-
ChemDiv Welcomes Peter Dmitriev and David Stark to Business Development Team, Announces Headquarters Expansion
10/26/2023
ChemDiv is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development.
-
ChemDiv Establishes a Cutting-edge Biology Facility in Portugal
8/16/2023
ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park, Cantanhede, Portugal.
-
ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection
8/13/2020
ChemDiv Inc., a fully integrated California-based CRO, announced the creation of a unique platform for development of drugs against coronavirus infection that would simplify and accelerate antiviral candidate selection.
-
Insilico Medicine and ChemDiv form a strategic drug discovery service alliance
10/16/2019
Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions.
-
ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration With Janssen
1/23/2018
ChemDiv announced at the 36th Annual J.P. Morgan Healthcare Conference the expansion of its hit identification collaboration with Janssen R&D and extending it into finding potent anti-infective drug candidates.
-
ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration
1/4/2018
The overall goal of the collaboration is to leverage DZNE's advanced research capabilities with ChemDiv's commercial expertise to efficiently design and validate new therapeutic candidates for treatment of Alzheimer's and other neurodegenerative diseases.
-
ChemDiv's Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs ChemDiv logo
11/6/2017
This collaboration with ChemDiv is aimed at assisting Tri-I TDI investigators with developing therapies across multiple therapeutic areas.
-
ChemDiv, Inc. Announces Multi-Year Hit Identification Collaboration With Janssen R&D
1/31/2017
-
ChemDiv, Inc. Release: Company Announces Key Milestones In Abbott Pharma Collaboration
1/11/2017
-
ChemDiv, Inc., Torrey Pines Investment And DZNE Announce Research Collaboration
10/17/2016
-
ChemDiv, Inc. Announces New Drug Discovery Collaboration Agreement With Cystic Fibrosis Foundation Therapeutics, Inc.
5/31/2016
-
ChemDiv, Inc. Announces Achievement Of A Development Milestone In A Drug Discovery Collaboration With Janssen Pharmaceutical
1/12/2016
-
ChemDiv, Inc. Receives Multiple Milestones in Major Drug Discovery Collaboration With Eli Lilly and Company
12/19/2012
-
Coare Biostechnology and ChemDiv, Inc. Establish Co-Marketing and Service Collaboration
11/8/2012
-
UCB, Inc. and ChemDiv Research Institute Conclude First Phase of Discovery Chemistry Collaboration
6/13/2012
-
ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica N.V. and Tibotec Pharmaceuticals Ltd
12/20/2011
-
Emerald BioStructures and ChemDiv, Inc. Establish Co-Marketing Collaboration
3/28/2011
-
ChemDiv, Inc. Opens the Unique Chemistry E-Commerce Store Offering the World's Largest Small Molecule Inventory
1/12/2011
-
Viriom Selects ChemDiv, Inc. to Develop HIV Program
10/19/2009